Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts

Anne M. Neilan, MD, MPH[1, 2, 3, 4]; Elena Losina, PhD[4, 5, 6, 7]; Audrey C. Bangs, BA[3]; Clare Flanagan, MPH[3]; Christopher Panella, BA[3]; G. Ege Eskibozkurt, BA[3]; Amir Mohareb, MD[2, 3, 4]; Emily P. Hyle, MD, MSc[2, 3, 4, 8]; Justine A. Scott, MPH[3]; Milton C. Weinstein, PhD[9]; Mark J. Siedner, MD, MPH[2, 3, 4, 10]; Krishna P. Reddy, MD, MS[3, 4, 11]; Guy Harling, ScD, MPH[10,12,13,14]; Kenneth A. Freedberg, MD, MSc[2, 3, 4, 9, 15]; Fatma M. Shebl, MD, PhD [3, 4]; Pooyan Kazemian, PhD[3, 4*]; Andrea L. Ciaranello, MD, MPH[2, 3, 4, 8*]

* PK and ALC contributed equally to this work.

1. Division of General Academic Pediatrics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA
2. Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4. Harvard Medical School, Boston, MA
5. Orthopedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA

6. Policy and Innovation eValuation in Orthopedic Treatments (PIVOT) Center, Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA
7. Department of Biostatistics, Boston University School of Public Health, Boston, MA
8. Harvard University Center for AIDS Research, Cambridge, MA
9. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA
10. Africa Health Research Institute, KwaZulu-Natal, South Africa
11. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA
12. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
13. Institute for Global Health, University College London, London, UK
14. MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa
15. Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA

Corresponding author:

Anne M. Neilan, MD, MPH

Medical Practice Evaluation Center

100 Cambridge Street, Suite 1600

Boston, MA 02114, USA

Phone: (617) 724-9708

Fax: (617) 726-4120

Email: aneilan@mgh.harvard.edu

SUMMARY

Low-cost (≤$5), repeat screening of asymptomatic people would decrease infections and deaths and be cost-effective even when epidemics are slowing; if test costs are ≥$50, at R_e <1.6 restricting testing to those with symptoms would be economically preferred.

ABSTRACT

Background

We projected the clinical and economic impact of alternative testing strategies on COVID-19 incidence and mortality in Massachusetts using a microsimulation model.

Methods

We compared four testing strategies: 1) Hospitalized: PCR testing only patients with severe/critical symptoms warranting hospitalization; 2) Symptomatic: PCR for any COVID-19-consistent symptoms, with self-isolation if positive; 3) Symptomatic+asymptomatic-once: Symptomatic and one-time PCR for the entire population; and, 4) Symptomatic+asymptomatic-monthly: Symptomatic with monthly re-testing for the entire population. We examined effective reproduction numbers (R_e, 0.9-2.0) at which policy conclusions would change. We assumed homogeneous mixing among the Massachusetts population (excluding those residing in long-term care facilities). We used published data on disease progression and mortality, transmission, PCR sensitivity/specificity (70/100%) and costs. Model-projected outcomes included infections, deaths, tests performed, hospital-days, and costs over 180-days, as well as incremental cost-effectiveness ratios (ICER, $/quality-adjusted life-year [QALY]).

Results

At R_e 0.9, Symptomatic+asymptomatic-monthly vs. Hospitalized resulted in a 64% reduction in infections and a 46% reduction in deaths, but required >66-fold more tests/day with 5-fold higher costs. Symptomatic+asymptomatic-monthly had an ICER <$100,000/QALY only when $R_e \geq 1.6$; when test cost was ≤$3, every 14-day testing was cost-effective at all R_e examined.

Conclusions

Testing people with any COVID-19-consistent symptoms would be cost-saving compared to testing only those whose symptoms warrant hospital care. Expanding PCR testing to asymptomatic people would decrease infections, deaths, and hospitalizations. Despite modest sensitivity, low-cost, repeat screening of the entire population could be cost-effective in all epidemic settings.

Keywords: COVID-19, testing, screening, PCR, cost-effective

INTRODUCTION

Massachusetts experienced a major COVID-19 outbreak beginning in March 2020 after a biotechnology convention, which was subsequently fueled by transmission in communities living in multi-generational and multi-family housing [1]. In the United States, restricted testing capacity early in the pandemic led states such as Massachusetts to test only severely symptomatic people and/or those with a known exposure [2]. While some have argued that testing must be highly sensitive in order to be of value to guide reopening [3], others have argued that sensitivity can be sacrificed if tests are rapid, low-cost, and frequent [4,5]. Despite the variable clinical sensitivity of SARS-CoV-2 polymerase chain reaction (PCR) testing, expanded testing programs could reduce transmissions by increasing isolation of infectious people, thereby reducing hospitalizations and deaths. Widely available testing could also allow for the safer resumption of economic and social activity by providing surveillance for any "second wave" of infection [6]. Such resumptions of public life may also benefit those with non-COVID-related health issues who may avoid seeking care due to concerns about acquiring COVID-19 [7].

To date, no national testing strategy has been articulated [8]. Since new infections peaked in late April [9], Massachusetts has used test positivity rates as a key indicator to guide gradual re-opening, after implementing strategies to reduce transmission risk [6]. In Massachusetts and elsewhere, planning is essential for utilization of key limited resources, such as testing and hospital beds, since mitigation strategies need to be able to pivot rapidly as epidemic growth scenarios change. Our goal was to examine the clinical and economic impact of screening strategies on COVID-19 in Massachusetts.

METHODS

Analytic overview

We developed a dynamic state-transition microsimulation model, the CEACOV (Clinical and Economic Analysis of COVID-19 Interventions) model, to reflect the natural history, diagnosis, and treatment of COVID-19. We modeled four testing strategies for all Massachusetts residents (excluding those residing in long-term care facilities): 1) Hospitalized: PCR testing only of those who develop severe illness (*i.e.*, warranting hospital care), reflecting common practices in Massachusetts through late April 2020 [2]; 2) Symptomatic: Hospitalized and PCR for people with any COVID-19-consistent symptoms who self-isolate if positive;
3) Symptomatic+asymptomatic-once: Symptomatic and a one-time PCR for the entire population; 4) Symptomatic+asymptomatic-monthly: Symptomatic+asymptomatic once and re-testing every 30 days of those who test negative and remain asymptomatic (Supplementary Figure 1). For those who are not hospitalized, we assume a positive PCR test leads to self-isolation in the community. We projected clinical outcomes (infections, COVID-19-related mortality, quality-adjusted life-years [QALYs]), and COVID-19-related resource utilization (tests, hospital and intensive care unit (ICU) beds, self-isolation days), and costs for Massachusetts (6.9 million people, excluding long-term care facility residents) over a 180-day horizon. We report incremental cost-effectiveness ratios (ICER: difference in cost divided by difference in quality-adjusted life-years [$/QALY]) from a healthcare sector perspective (Supplementary Methods). The threshold at which interventions are considered cost-effective is a normative value that varies by setting; for the sake of interpretability, we define a strategy as "cost-effective" if its ICER is below $100,000/QALY [10].

CEACOV model structure

Cohort and disease progression

At model start, a closed pre-intervention cohort is seeded with a user-defined proportion of age-stratified individuals (0-19, 25-59, ≥60 years) who are either infected with or susceptible to the SARS-CoV-2 virus. If infected, individuals face daily age-stratified probabilities of disease progression through seven health/disease states, including latent infection, asymptomatic illness, mild/moderate illness, severe illness (warranting hospitalization), critical illness (warranting intensive care), recuperation, and recovery (Supplementary Figure 2). We assume recovered individuals are immune from repeat infection for the 180-day modeled horizon [11]. Susceptible and recovered individuals may also present for testing with symptoms due to non-COVID-19 conditions ("COVID-19-like illness").

Testing

Individuals can experience a daily probability of undergoing SARS-CoV-2 testing. Each PCR testing strategy includes test sensitivity/specificity, turnaround time, and testing frequency.

Transmission

In the model, infected individuals have an equal probability of contacting susceptible individuals and transmitting SARS-CoV-2. The effective reproduction number (R_e) captures the average number of secondary cases per infected individual in the cohort; based on Massachusetts data, this was estimated to be 0.9 in late April 2020 (Supplementary Methods and Supplementary Table 1). People with a positive test result or symptom screen can isolate in the community or in the hospital, which further decreases transmission.

Resource use

The model tallies tests, COVID-19-related use of hospital and ICU bed-days, as well as days spent self-isolating.

Model inputs

Cohort and disease progression

We derived the initial distribution of COVID-19 disease severity by age from the Massachusetts Census and Department of Public Health (Table 1) [12,13]. Disease progression and COVID-19-related mortality are derived from data from China and Massachusetts and calibrated from mid-March to May 1, 2020 to deaths in Massachusetts (excluding those occurring in long-term care facilities) (Table 1 and Supplementary Table 1) [13–18].

Testing and associated transmission reduction

PCR test sensitivity/specificity are assumed to be 70%/100% (Table 1) [19,20]. In all strategies, patients with severe or critical illness are eligible for diagnostic testing and are hospitalized regardless of PCR test result. Transmission is reduced by 90% for hospitalized people due to infection control and isolation practices (Table 1 and Supplementary Methods). In the expanded PCR-based strategies, self-isolation among those in the community with a positive PCR test leads to a 65% transmission reduction [21]; those who test negative do not self-isolate (incorporating the potential for transmissions associated with false-negative tests). PCR test acceptance is assumed to be 80% for those who are asymptomatic or have mild/moderate illness at the time of testing, and 100% for those with severe or critical illness.

Epidemic scenarios

The analysis of screening strategies begins after the period of model validation and calibration (mid-March through late April, Supplementary Methods). For the first month of the simulation, corresponding to May 1, 2020 to May 31, 2020, R_e remains 0.9 (Supplementary Table 1). To account for the uncertain trajectory of the epidemic as reopening plans are implemented, we model three scenarios representing epidemics with distinct R_e values in the absence of expanded testing (*i.e.*, Hospitalized), beginning on June 1, 2020: 1) Slowing (June 1, 2020 R_e=0.9), suggesting epidemic growth would remain the same as during May (*e.g.* stay-at-home advisory and non-essential business closures); 2) Intermediate (June 1, 2020 R_e=1.3), suggesting modest increase in epidemic growth; and, 3) Surging (June 1, 2020 R_e=2.0), suggesting an R_e closer to late March/early April Massachusetts estimates (R_e=2.6-5.9, Supplementary Table 1). We also identified threshold values for the R_e at which policy conclusions would change. Transmission probabilities are based on time spent in each health state (Table 1).

Costs and cost-effectiveness

PCR test cost is $51 [22]. Patients requiring hospitalization accrue per-day costs (hospital: $1,640; ICU: $2,680) [23–25]. We use projected deaths to estimate quality-adjusted discounted life-years lost per strategy (Supplementary Methods) [26].

Sensitivity and scenario analyses

In each of the three epidemic growth scenarios, we vary PCR sensitivity (30-100%), test acceptance (15-100% for asymptomatic or mild/moderate symptoms), transmission reduction after a positive test (33-100%), presentation to hospital with severe disease (50-100%), ICU survival (20-80%), testing program costs (including additional outreach costs of offering PCR testing even if declined, $1-$26), and hospital

care costs ($820-$3,880). In multiway sensitivity analyses, we vary key parameters simultaneously. In additional analyses, we examined implementation of these testing strategies on April 1, 2020 vs. May 1, 2020; the R_e threshold at which conclusions about the preferred strategy shifted (R_e 1.3-2.0); the frequency of retesting in Symptomatic+asymptomatic-monthly (up to daily); patterns of presenting with COVID-19-like illness; and, the impact of costs associated with lost productivity due to hospitalization or positive PCR test results and averted mortality. Further details of methods, as well as model calibration and validation, are in the Supplementary Material.

RESULTS

Base case outcomes

Clinical outcomes

All the expanded screening strategies would reduce infections and deaths compared to Hospitalized. In all epidemic scenarios, Symptomatic+asymptomatic-monthly would lead to the most favorable clinical outcomes and Hospitalized would lead to the least favorable outcomes; in the slowing scenario, Symptomatic+asymptomatic-monthly vs. Hospitalized resulted in 209,500 vs. 577,700 infections (64% reduction) and 1,700 vs. 3,100 deaths (46% reduction) (Table 2, top section). As R_e increases, compared to Hospitalized, more expansive screening strategies would lead to greater reductions in infections and deaths (Table 2, bottom section). As R_e increases, the expanded screening strategies, compared with Hospitalized, would result in a greater reduction in peak prevalence and lower reduction in the susceptible proportion of the population (Figures 1A-C).

Resource utilization and costs

In all epidemic growth scenarios, Symptomatic would lead to lower total costs compared to Hospitalized. In the slowing scenario, Symptomatic+asymptomatic-monthly would lead to the greatest reduction in cumulative bed-days compared to Hospitalized: 77,300 vs. 126,000 hospital bed-days (39% reduction) and 45,600 vs. 76,600 ICU bed-days (40% reduction) but would require >66-fold times more tests/day (192,200 vs. 2,900) at 5-fold higher total costs ($2.0 billion vs. $439 million) (Tables 2 and 3). In the slowing and intermediate scenarios, peak hospital bed use is similar across all strategies. In the surging scenario, however, all other PCR-based strategies would reduce peak hospital and ICU bed use compared to Hospitalized: hospital beds (7,100 vs. 2,300-4,600) and ICU beds (4,100 vs. 1,200-2,500) (Table 3, bottom section). Supplementary Table 2 reports results/million people.

Cost-effectiveness outcomes

Under all epidemic growth scenarios considered, Symptomatic would be clinically superior and cost-saving compared to Hospitalized (Table 2). Symptomatic+asymptomatic-monthly would have an ICER <$100,000/QALY compared to Symptomatic only in the surging scenario ($33,000/QALY). ICERs increase steeply as R_e declines (Table 2).

Sensitivity and scenario analyses

Clinical outcomes and resource use

The impact of variation in clinical model input parameters on infections and deaths would be greatest in the surging scenario (Supplementary Figures 3A-F). Varying rates of presentation to hospital care and ICU survival would lead to large changes in mortality, which remain substantial (slowing scenario: 1,300-

2,400 deaths/180-days) even under optimistic assumptions (*i.e.*, 100% presentation to hospital with severe illness or 80% ICU survival) (Supplementary Figures 3D-F). If expanded PCR testing started April 1, 2020, compared to May 1, 2020, we project that PCR-based strategies would have averted 103,000-176,900 infections (Supplementary Figures 4A-C) and 90-260 deaths in April alone (4D-F).

Cost-effectiveness

In one-way sensitivity analyses, the economically preferred strategy in each epidemic scenario was most sensitive to test acceptance, the transmission reduction after a positive PCR test, and PCR test costs (Supplementary Tables 3-11). In the surging scenario, Symptomatic+asymptomatic-monthly would not be cost-effective if we assume low test acceptance (15%), half the transmission reduction after a positive test (33%), or triple PCR test costs ($154). Symptomatic+asymptomatic-monthly would become cost-effective in the intermediate and slowing scenarios only with reductions in test costs (intermediate: ≤$13 slowing: ≤$5). If costs decrease for PCR assays, many combinations of program and assay costs Symptomatic+asymptomatic-monthly strategy would be cost-effective or cost-saving (Supplementary Figure 5).

Holding other parameters equal to the base case, Symptomatic+asymptomatic-monthly would become cost-effective at an R_e value ≥1.6 (Supplementary Table 12). The frequency of repeat testing with Symptomatic+asymptomatic-monthly is also influential; in the surging scenario, Symptomatic+asymptomatic-monthly would no longer be cost-effective if tests occur more frequently than every 30 days (Supplementary Table 13), however if test costs were ≤$3, then testing as frequently as every 14-days would be cost-effective in all epidemic scenarios (Figure 2). While total costs would vary widely with rates of COVID-19-like illness, cost-effectiveness conclusions would not change

(Supplementary Table 14). Conclusions are similar even when costs associated with lost productivity or averted COVID-related mortality are included (Supplementary Table 15).

DISCUSSION

Using a microsimulation model, we projected the COVID-19 epidemic in Massachusetts from May 1, 2020 to November 1, 2020 under slowing, intermediate, and surging epidemic growth scenarios, to examine the clinical and economic impact of four testing strategies.

Expanded PCR testing beyond those with severe symptoms would reduce morbidity and mortality across a range of epidemic scenarios. In all R_e scenarios, we estimate substantial reductions in mortality (1.8- to 2.6-fold lower) with Symptomatic+asymptomatic-monthly compared to Hospitalized. Our R_e values encompass published estimates for Massachusetts during the study period [27–29]. Importantly, the slowing scenario likely reflects Massachusetts's response through June 2020 [9], and the surging scenario provides important insight for elsewhere in the United States where infections are increasing.

We further estimate that if expanded PCR testing had been widely available in Massachusetts from April 1, 2020 to May 1, 2020, 103,000-176,900 infections and 90-260 deaths would have been averted during that one month alone. Given the average time from infection to hospitalization and death (~9 days and ~28 days, respectively), earlier expanded testing might also have facilitated timely recognition of epidemic trends and closure policies. Policies that reduce R_e at scale (*e.g.*, stay-at-home advisories), as occurred in Massachusetts even while PCR testing was scarce, are likely to be more effective than any of the modeled testing strategies [30,31]. Similar to conclusions from other studies [27,32–35], our findings suggest that looser restrictions on social distancing regulations (which can lead to a higher R_e) would require more aggressive testing, paired with individual behavioral measures, to control the epidemic.

All the expanded screening strategies would lead to reductions in key hospital resource use as well as fewer days spent self-isolating compared to Hospitalized. In Massachusetts, an estimated 9,500 hospital beds and 1,500 ICU beds were available at the peak of the surge capacity, of which 3,800 and 1,440 were used [9,36]. None of the modeled scenarios exceeded peak hospital bed capacity; however, we projected 23-75% of available hospital beds would be needed by people with COVID-19. In all scenarios, we projected peak ICU bed use close to or exceeding capacity (1,200-4,100). While some assumptions are uncertain (*e.g.* proportion of people presenting to the hospital with severe disease, probability of ICU survival) the substantial burden of severe and critical illness we project in all scenarios has important implications for healthcare globally – resources redirected for COVID-related illness may jeopardize the ability to care for other diseases.

In all examined epidemic growth scenarios, Symptomatic testing would be cost-saving compared to Hospitalized. At any R_e above 1.6, Symptomatic+asymptomatic-monthly would be the most efficient use of resources, unless test acceptance is very low (15%). Importantly, at these higher R_e values, screening the entire population only one time would be an inefficient strategy without repeat screening for those testing negative. ICERs were highly sensitive to PCR test costs. If low-cost testing were available at $5/test, it would be cost-effective or cost-saving to offer repeat testing in all epidemic scenarios. In the absence of rapid, low-cost, widely available testing, states will also need to prepare themselves to pivot testing strategies as the epidemic shifts.

In the slowing and intermediate scenarios, as of July 2020, Massachusetts would have test capacity to conduct the economically preferred Symptomatic strategy (approximately 12,000/day

estimated tests conducted statewide vs. 4,800-5,900 model-projected tests) [9]. However, in the surging scenario, the projected average of 203,100 tests/day (36.6 million/180 days) required to conduct the cost-effective Symptomatic+asymptomatic-monthly strategy would greatly exceed current capacity; notably, daily testing of the entire population in this scenario led to >3 million projected tests/day. Large-scale testing has been achieved early in the epidemic in some settings: in March 2020, South Korea was testing 20,000 people/day [37]. Newer high throughput machines may process thousands of tests per day, rendering such an approach potentially feasible in the near future [38]. Additionally, the number of tests used for people without COVID-19 is uncertain; we assumed high rates of COVID-like-illness (adding approximately 2,800 tests/day) in the base case, however, it is likely, particularly in summer months, that fewer people would seek testing. Given that the economically preferred strategy changes depending on R_e, implementation of the most cost-effective testing strategy will require careful planning and real-time epidemic monitoring in each setting to adapt to changing R_e. Furthermore, while currently an aspiration, low-cost, rapid turnaround testing, even with current imperfect test sensitivity would be cost-effective even in low R_e settings. While critical supply chain issues and other factors precluded widespread testing in the US early in the pandemic, even now, expanding testing capacity must remain a focus of national efforts. Given that scaling current technologies may not be feasible in all settings, additional innovative strategies including pooled-, rapid antigen- and home self-testing, should be examined [39,40].

The impact of any testing strategy depends on the actions that policymakers, employers, and individuals take in response. Compared to testing only those with severe symptoms, monthly routine testing averted only 58-64% of infections, whereas daily testing averted 75-91% of

infections. Our results emphasize how policies that support isolating people infected with COVID-19 are essential; when an individual is less adherent to self-isolation after a positive test (*i.e.*, lower transmission reduction), the benefits of testing are greatly reduced. In Iceland, broad testing led to only 6% of the population being tested, with 34% of an invited random sample presenting for testing [41]. In the surging scenario, at low test acceptance rates (15%) among those with no or mild symptoms, Symptomatic+asymptomatic-monthly would no longer be cost-effective. In Massachusetts, SARS-CoV-2 testing often does not require co-pays, and sufficient personal protective equipment permits safe testing [1,2]. Nevertheless, people may avoid testing due to concerns such as physical discomfort, missing work, or stigma. While the Family Medical and Leave Act may provide support for those eligible who test positive (or if family members test positive), not all workers may be aware of their rights or have compliant employers [42]. Federal and setting-specific incentives for infected people to self-isolate should be considered (*e.g.*, childcare or workplace incentives) [43].

This analysis has important limitations. First, we assume homogenous population mixing. This assumption may over- or under-estimate the benefits of PCR testing; however, we have calibrated our model to reflect observed data, using a transmission multiplier. When relevant, we selected values or made assumptions which would provide a conservative estimate of the benefits of testing (PCR sensitivity, test cost, transmission reduction after a negative test), and then varied these values widely in sensitivity analyses. Second, we do not address supply chain lapses which could impact the feasibility of implementing these strategies. Third, we exclude several factors that may result from expanded testing that would render these strategies even more cost-effective, including averting quality-of-life reductions due to COVID-related morbidity or self-quarantine-related mental health issues [44], preventing school closure-related workforce gaps [45], increasing economic purchasing, and enabling economic activity to

reopen due to reduced COVID incidence [33]. We also assume that transmissions vary with a constant daily rate by disease state; emerging data suggest that infectivity may be highest early after acquisition of the virus [46]. If true, testing strategies which diagnose people in early or asymptomatic stages of infection would be of higher value. Finally, we do not model contact tracing, which is likely to be a critical tool to respond to a patchwork of surging outbreaks over time.

Testing people with any COVID-19-consistent symptoms would be cost-saving compared to testing only those whose symptoms warrant hospital care. Expanding SARS-CoV-2 PCR testing to asymptomatic people would reduce infections, deaths, and hospital resource use. Despite modest sensitivity, low-cost, repeat screening of the entire population could be cost-effective in all epidemic settings.

NOTES

AUTHOR ROLES

All authors contributed substantively to this manuscript in the following ways: study and model design (all authors), data analysis (AMN, ACB), interpretation of results (all authors), drafting the manuscript (AMN, ACB, AM, PK), and critical revision of the manuscript (all authors) and final approval of submitted version (all authors).

FUNDING

This work was supported by the Eunice Kennedy Shriver National Institute for Child Health and Human Development [K08 HD094638 to AMN], the National Institute of Allergy and Infectious Disease at the National Institutes of Health [T32 AI007433 to AM, R37AI058736-16S1 to KAF], and the Wellcome Trust [210479/Z/18/Z to GH].

The content is solely the responsibility of the authors, and the study's findings and conclusions do not necessarily represent the official views of the National Institutes of Health, the Wellcome Trust, or other funders.

ACKNOWLEDGMENTS

The authors gratefully acknowledge Christopher Alba, Giulia Park, and Tijana Stanic for their assistance in preparing the manuscript for publication.

CONFLICTS OF INTEREST AND FINANCIAL DISCLOSURES

E.L. reports personal fees for being adviser for osteoarthritis-related work from Pfizer and Lilly, outside the submitted work. M.S. reports an investigator-initiated research grant from ViiV Pharmaceuticals, outside the submitted work. M.W. reports personal fees from Quadrant Health Economics and Precision HEOR, outside the submitted work. All other authors have no conflicts of interest or financial disclosures.

REFERENCES

1. Boston Public Health Commission. Mayor Walsh, Massachusetts General Hospital announce results of antibody and COVID-19 testing for Boston residents. 2020; Available at: https://www.bphc.org/onlinenewsroom/Blog/Lists/Posts/Post.aspx?ID=1297. Accessed 29 May 2020.

2. Massachusetts Department of Public Health. Testing of persons with suspect COVID-19. 2020; Available at: https://www.mass.gov/doc/covid-19-pui-criteria/download. Accessed 19 May 2020.

3. Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection — challenges and implications. N Engl J Med **2020**; 383:e38. Available at: http://www.nejm.org/doi/10.1056/NEJMp2015897. Accessed 13 August 2020.

4. Rockefeller Foundation. COVID-19 national testing and tracing action plan. Available at: https://www.rockefellerfoundation.org/national-covid-19-testing-and-tracing-action-plan/. Accessed 13 August 2020.

5. Rapid Tests. Available at: https://www.rapidtests.org. Accessed 13 August 2020.

6. Mass.gov. Reopening Massachusetts. 2020. Available at: https://www.mass.gov/doc/reopening-massachusetts-may-18-2020/download. Accessed 7 July 2020.

7. Lange SJ. Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions — United States, January-May 2020. MMWR Morb Mortal Wkly Rep **2020**; 69. Available at: https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e2.htm. Accessed 13 August 2020.

8. Centers for Disease Control and Prevention. CDC activities and initiatives supporting the COVID-19 response and the president's plan for opening America up again. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/downloads/php/CDC-Activities-Initiatives-for-COVID-19-Response.pdf.

9. Massachusetts Department of Public Health. Massachusetts Department of Public Health COVID-19 Dashboard. 2020. Available at: https://www.mass.gov/doc/covid-19-dashboard-may-1-2020/download. Accessed 15 July 2020.

10. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. New Eng J Med **2014**; 371:796–797. Available at: https://doi.org/10.1056/NEJMp1405158. Accessed 18 June 2020.

11. Bao L, Deng W, Gao H, et al. Lack of reinfection in Rhesus macaques infected with SARS-CoV-2. BioRxiv 990226 [Preprint] **2020**; Available at: http://biorxiv.org/lookup/doi/10.1101/2020.03.13.990226. Accessed 21 May 2020.

12. U.S. Census Bureau. American Community Survey 1-year estimates (2018). 2018. Available at: http://censusreporter.org/profiles/04000US25-massachusetts/. Accessed 16 April 2020.

13. Massachusetts Department of Public Health. Archive of COVID-19 cases in Massachusetts. Available at: https://www.mass.gov/info-details/archive-of-covid-19-cases-in-massachusetts. Accessed 16 April 2020.

14. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med **2020**; 26:672–675. Available at: https://www.nature.com/articles/s41591-020-0869-5. Accessed 16 July 2020.

15. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci **2020**; Available at: https://doi.org/10.1007/s11427-020-1661-4. Accessed 16 April 2020.

16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet **2020**; 395:1054–1062. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/abstract. Accessed 16 April 2020.

17. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep **2020**; 69. Available at: https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm. Accessed 16 April 2020.

18. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). World Health Organization, 2020. Available at: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19). Accessed 16 April 2020.

19. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv 2020021120021493 [Preprint] **2020**; Available at: http://medrxiv.org/lookup/doi/10.1101/2020.02.11.20021493. Accessed 21 May 2020.

20. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA **2020**; 323:1843–1844. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066521/. Accessed 21 May 2020.

21. Wolf MS, Serper M, Opsasnick L, et al. Awareness, attitudes, and actions related to COVID-19 among adults with chronic conditions at the onset of the U.S. outbreak. Ann Intern Med **2020**; Available at: https://www.acpjournals.org/doi/10.7326/M20-1239. Accessed 18 June 2020.

22. Centers for Medicare and Medicaid Services. Medicare administrative contractor (MAC) COVID-19 test pricing. 2020. Available at: https://www.cms.gov/files/document/mac-covid-19-test-pricing.pdf. Accessed 21 May 2020.

23. Cox C, Rudowitz R, Neuman T, Cubanski J, Rae M. How health costs might change with COVID-19. Peterson-Kaiser Family Foundation (KFF) Health System Tracker. 2020; Available at: https://www.healthsystemtracker.org/brief/how-health-costs-might-change-with-covid-19/. Accessed 4 June 2020.

24. Rae M, Claxton G, Kurani N, McDermott D, Cox C. Potential costs of COVID-19 treatment for people with employer coverage. Peterson-Kaiser Family Foundation (KFF) Health System Tracker. 2020; Available at: https://www.healthsystemtracker.org/brief/potential-costs-of-coronavirus-treatment-for-people-with-employer-coverage/. Accessed 4 June 2020.

25. COVID-19: The projected economic impact of the COVID-19 pandemic on the US healthcare system. FAIR Health, 2020. Available at: https://s3.amazonaws.com/media2.fairhealth.org/brief/asset/COVID-19%20-%20The%20Projected%20Economic%20Impact%20of%20the%20COVID-19%20Pandemic%20on%20the%20US%20Healthcare%20System.pdf. Accessed 7 July 2020.

26. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making **2006**; 26:410–420. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634296/. Accessed 4 June 2020.

27. Unwin H, Mishra S, Bradley V, et al. Report 23: State-level tracking of COVID-19 in the United States. Imperial College London, 2020. Available at: http://spiral.imperial.ac.uk/handle/10044/1/79231. Accessed 26 May 2020.

28. Systrom K, Vladeck T. Massachusetts Rt. Available at: https://rt.live/us/MA. Accessed 15 July 2020.

29. Abbott S, Hellwell J, Thompson RN, et al. National and subnational estimates for the United States of America. Available at: https://epiforecasts.io/covid/posts/national/united-states/. Accessed 15 July 2020.

30. Abouk R, Heydari B. The immediate effect of COVID-19 policies on social distancing behavior in the United States. medRxiv 2020040720057356 [Preprint] **2020**; Available at: https://www.medrxiv.org/content/10.1101/2020.04.07.20057356v2. Accessed 22 June 2020.

31. Dave D, Friedson A, Matsuzawa K, Sabia J. When do shelter-in-place orders fight COVID-19 best? Policy heterogeneity across states and adoption time. National Bureau of Economic Research, 2020. Available at: http://www.nber.org/papers/w27091. Accessed 22 June 2020.

32. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med **2020**; 27. Available at: https://academic.oup.com/jtm/article/27/2/taaa021/5735319. Accessed 16 April 2020.

33. Eichenbaum MS, Rebelo S, Trabandt M. The macroeconomics of epidemics. National Bureau of Economic Research, 2020. Available at: http://www.nber.org/papers/w26882. Accessed 22 June 2020.

34. Kucharski AJ, Klepac P, Conlan AJK, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: A mathematical modelling study. Lancet Infect Dis **2020**; Available at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30457-6/abstract. Accessed 22 June 2020.

35. Firth JA, Hellewell J, Klepac P, et al. Combining fine-scale social contact data with epidemic modelling reveals interactions between contact tracing, quarantine, testing and physical distancing for controlling COVID-19. medRxiv 2020052620113720 [Preprint] **2020**; Available at: https://www.medrxiv.org/content/10.1101/2020.05.26.20113720v2. Accessed 22 June 2020.

36. Massachusetts Department of Public Health. Baker-Polito administration provides update on hospital surge capacity. 2020. Available at: https://www.mass.gov/news/baker-polito-administration-provides-update-on-hospital-surge-capacity.

37. Pancevski B. Some nations look to mass testing for faster way out of coronavirus crisis. Wall Street Journal. 2020; Available at: https://www.wsj.com/articles/some-nations-look-to-mass-testing-for-faster-way-out-of-coronavirus-crisis-11585758518. Accessed 15 July 2020.

38. Broad Institute. COVID-19 Diagnostic Processing Dashboard. Available at: https://covid19-testing.broadinstitute.org/. Accessed 30 June 2020.

39. Lim KL, Johari NA, Wong ST, et al. A novel strategy for community screening of SARS-CoV-2 (COVID-19): Sample pooling method. PLoS ONE **2020**; 15:e0238417.

40. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev **2020**; 8:CD013705.

41. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med **2020**; 382:2302–2315.

42. U.S. Department of Labor. Families First Coronavirus Response Act: Employee paid leave rights. Available at: https://www.dol.gov/agencies/whd/pandemic/ffcra-employee-paid-leave. Accessed 7 July 2020.

43. Centers for Disease Control and Prevention. Case investigation and contact tracing: Part of a multipronged approach to fight the COVID-19 pandemic. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/principles-contact-tracing.html. Accessed 30 June 2020.

44. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. Emerging Infect Dis **2004**; 10:1206–1212.

45. Bayham J, Fenichel EP. Impact of school closures for COVID-19 on the US health-care workforce and net mortality: A modelling study. Lancet Public Health **2020**; 5:e271–e278.

46. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med **2020**; 382:2081–2090. Available at: http://www.nejm.org/doi/10.1056/NEJMoa2008457. Accessed 29 May 2020.

47. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases. Overall percentages of visits for ILI and percentage of visits for ILI by age group reported by a subset of ILINet providers. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data. Accessed 4 July 2020.

48. Chen X, Yu B. First two months of the 2019 coronavirus disease (COVID-19) epidemic in China: Real-time surveillance and evaluation with a second derivative model. Glob Health Res Policy **2020**; 5:7. Available at: https://doi.org/10.1186/s41256-020-00137-4. Accessed 16 April 2020.

49. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis **2020**; 26. Available at: https://wwwnc.cdc.gov/eid/article/26/7/20-0282_article. Accessed 16 April 2020.

Table 1. Input parameters for a model of COVID-19 disease and testing in Massachusetts

Parameter	Value	
Cohort characteristics		
Initial age distribution of cohort, % [12]		
0-19 years	25	
20-59	56	
≥60	19	
Initial distribution of health states on May 1, 2020, % [13] [a]		
Susceptible	89.38	
Latent	0.52	
Asymptomatic	0.91	
Mild/moderate illness	1.49	
Severe illness	0.04	
Critical illness	0.02	
Recuperation	0.01	
Recovered	7.63	
Health state transition probabilities, by ultimate stage of disease, daily [14–16,18] [b]		
Asymptomatic		
Latent to asymptomatic	0.565	
Asymptomatic to recovered	0.099	
Mild/moderate		
Latent to asymptomatic	0.565	
Asymptomatic to mild/moderate	0.221	
Mild/moderate to recovered	0.095	
Severe	With hospital care	Without hospital care
Latent to asymptomatic	NA	0.565
Asymptomatic to mild/moderate	NA	0.221
Mild/moderate to severe	NA	0.143
Severe to recovered	0.091	0.063
Critical		
Latent to asymptomatic	NA	0.565
Asymptomatic to mild/moderate	NA	0.221
Mild/moderate to severe	NA	0.284
Severe to recovered	0.026	0.000
Severe to critical	0.105	0.143
Critical to recuperation	0.049	0.000
Recuperation to recovered	0.161	0.000

Table 1. Input parameters for a model of COVID-19 disease and testing in Massachusetts (continued)

Parameter	Value	
COVID-19-related mortality while critically ill, probability, daily [47]	With hospital care	Without hospital care
0-19 years	0.00001	0.118
20-59	0.004	0.166
≥60	0.050	0.203
Development of COVID-19-like illness symptoms among susceptible and recovered, probability, daily [47]		
Mild/moderate illness		
0-19 years	0.00005	
20-59	0.00005	
≥60	0.00008	
Severe illness		
0-19 years	0.00032	
20-59	0.00036	
≥60	0.00053	
Critical illness		
0-19 years	0.00009	
20-59	0.00010	
≥60	0.00015	
Presentation to hospital care with severe symptoms, probability [c]	0.80	
Test characteristics		
PCR test [19,20]		
Sensitivity, % [d]	70	
Specificity, %	100	
Turnaround time, days	1	
Test acceptance, probability		
Asymptomatic/mild illness/moderate illness	0.80	
Critical/severe illness	1.00	

Table 1. Input parameters for a model of COVID-19 disease and testing in Massachusetts (continued)

Parameter	Value	
Transmissions		
R_e		
May 1 – May 30	0.9	
By health state, probability, daily [32,48,49] [d]		
Latent	0.0000	
Asymptomatic	0.2024	
Mild/moderate illness	0.1948	
Severe illness	0.0135	
Critical illness	0.0107	
Recuperation	0.0135	
Recovery	0.0000	
Transmission reduction after test result, % [f]	Test positive	Test negative
Asymptomatic	65	0
Mild/moderate illness	65	0
Severe/critical/recuperation [f]	90	90
Costs (USD 2020)		
SARS-CoV-2 PCR assay [22]	51	
Hospital bed, daily [23–25]	1,640	
Intensive care unit, daily [23–25]	2,680	

Abbreviations: PCR, polymerase chain reaction; R_e, Effective reproduction number; USD, United States dollars

[a] Derived from model validation and calibration as described in the Supplementary Material.
[b] Average days spent in each health state stratified by clinical disease progression severity are presented in Supplementary Table 1. Health state transitions are shown in Supplementary Figure 2.
[c] Assumption; includes those with COVID-19 disease and those with COVID-19-like illness.
[d] Test sensitivity is 0% in the latent phase and otherwise does not vary by disease states.
[e] Daily transmission rates contribute to R_e.
[f] Assumptions for transmission reductions following test result are detailed in the Supplementary Material. In severe/critical/recuperation states, transmission reduction is due to hospitalization and thus is applied to all patients regardless of test result.

Table 2. Clinical and cost-effectiveness outcomes for a model of COVID-19 disease and testing in Massachusetts

	Undiscounted	Undiscounted	Discounted	Undiscounted	Discounted
	Incident infections, No. [a]	Deaths, No. [a]	Total QALYs lost, No. [b]	Healthcare costs, $ [a, c]	ICER, $/QALY [c]
Slowing scenario (June 1, 2020 R_e 0.9)					
Symptomatic	315,700	2,200	11,900	342,787,000	-
Hospitalized	577,700	3,100	16,400	439,495,000	dominated
Symptomatic+asymptomatic-once	268,100	2,000	10,500	605,505,000	194,000
Symptomatic+asymptomatic-monthly	209,500	1,700	8,900	2,024,106,000	908,000
Intermediate scenario (June 1, 2020 R_e 1.3)					
Symptomatic	680,600	3,400	18,300	488,896,000	-
Symptomatic+asymptomatic-once	579,200	3,000	16,100	727,290,000	110,000
Hospitalized	1,696,800	6,800	36,100	849,882,000	dominated
Symptomatic+asymptomatic-monthly	333,700	2,100	11,400	2,091,084,000	287,000
Surging scenario (June 1, 2020 R_e 2.0)					
Symptomatic	3,374,200	13,700	72,600	1,608,128,000	-
Symptomatic+asymptomatic-once	3,258,100	13,000	68,800	1,831,196,000	dominated
Hospitalized	4,444,300	18,300	97,200	2,090,289,000	dominated
Symptomatic+asymptomatic-monthly	1,884,000	7,100	37,700	2,757,024,000	33,000

Abbreviations: No., Number; PCR, Polymerase chain reaction; R_e, Effective reproduction number; $, US dollars; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year

Strategies are listed in order of increasing cost as per cost-effectiveness analysis convention.

[a] Includes 180-day horizon between simulated days May 1, 2020 and November 1, 2020.
[b] Total life-years lost were estimated from COVID-related deaths occurring over 180-days. Details are in the Supplementary Material.
[c] Incremental cost effectiveness ratios are calculated by dividing the difference in total healthcare-related costs by the difference in total QALYs lost compared to the next most expensive strategy. Dominated strategies are either more expensive and less effective than another strategy (strong dominance) or a combination of two other strategies (weak dominance). Total QALYs lost are discounted at 3%/year; because all healthcare costs occur in year one, costs are not discounted in the base case. Additional details of calculating ICERs may be found in the Supplementary Material.
Infections, deaths, and life-years lost are rounded to the nearest 100. Costs and ICERs are rounded to the nearest 1,000. In-text results describing percentages are calculated from unrounded results.

Table 3. Clinical and resource utilization outcomes for a model of COVID-19 disease and testing in Massachusetts

	PCR tests per simulation day, mean	PCR tests, total	Hospital bed-days		ICU bed-days		Cumulative self-isolation days
			Cumulative	Peak	Cumulative	Peak	
Slowing scenario (June 1, 2020 R_e 0.9)							
Hospitalized	2,900	521,800	126,300	2,200	76,600	1,000	-
Symptomatic	4,800	861,500	91,200	2,200	55,500	900	1,731,000
Symptomatic+asymptomatic-once	35,100	6,318,200	87,100	2,200	51,600	900	1,948,900
Symptomatic+asymptomatic-monthly	192,200	34,593,900	77,300	2,200	45,600	900	2,251,900
Intermediate scenario (June 1, 2020 R_e 1.3)							
Hospitalized	2,900	530,400	257,500	2,200	149,100	1,000	-
Symptomatic	5,900	1,053,100	133,100	2,200	80,700	900	2,802,000
Symptomatic+asymptomatic-once	36,300	6,534,100	123,200	2,200	70,800	900	2,897,300
Symptomatic+asymptomatic-monthly	193,500	34,823,700	93,400	2,200	56,300	900	2,942,600
Surging scenario (June 1, 2020 R_e 2.0)							
Hospitalized	3,100	549,300	639,800	7,100	377,300	4,100	-

Symptomatic	13,900	2,498,800	469,200	4,600	264,600	2,500	10,974,100
Symptomatic+asymptomatic-once	46,800	8,418,900	442,900	4,300	250,600	2,500	11,326,700
Symptomatic+asymptomatic-monthly	209,300	37,672,900	265,700	2,300	144,600	1,200	10,694,400

Abbreviations: PCR, Polymerase chain reaction; ICU, Intensive care unit; R_e, Effective reproduction number

Includes events occurring during the 180-day horizon between simulated days May 1, 2020 and November 1, 2020. Strategies are listed by increasing number of tests utilized. PCR tests, hospital bed-days, ICU bed-days, and self-isolation days are rounded to the nearest 100. In-text results describing percentages are calculated from unrounded results. Cumulative self-isolation days are estimated in addition to the Hospitalized strategy.

FIGURE LEGENDS

Figure 1. Model-projected SARS-CoV-2 infection prevalence and proportion of susceptible cohort

For the modeled strategies, prevalent COVID-19 cases over time are plotted as solid lines on the left vertical axis, while the percentages of the cohort remaining susceptible to infection over time are plotted as dotted lines on the right vertical axis. People with SARS-CoV-2 are no longer considered prevalent when they have recovered (Supplementary Figure 1). Results shown represent the population of Massachusetts. Testing strategies are denoted by different colored lines. Panel A represents a slowing scenario in which the effective reproduction number (R_e) on June 1, 2020 is 0.9. Panel B represents an intermediate scenario in which R_e on June 1, 2020 is 1.3, and panel C represents a surging scenario in which R_e on June 1, 2020 is 2.0.

Abbreviations: R_e, Effective reproduction number; PCR, Polymerase chain reaction

Figure 2. Two-way sensitivity analyses: PCR test cost and frequency

In this two-way sensitivity analysis, PCR test cost and frequency were varied. Incremental cost-effectiveness ratios (ICERs) are reported in $/QALY for Symptomatic+asymptomatic-monthly testing versus the next least costly strategy. The "X" represents the base case.

Abbreviations: R_e, Effective reproduction number; ICER, Incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; PCR, Polymerase chain reaction;

A. Slowing scenario (June 1, 2020 R_e 0.9)



B. Intermediate scenario (June 1, 2020 R_e 1.3)



C. Surging scenario (June 1, 2020 R_e 2.0)





A.
ICER for Symptomatic+asymptomatic-monthly strategy compared to the next less costly strategy in slowing scenario (June 1, 2020 R_e 0.9)



B.
ICER for Symptomatic+asymptomatic-monthly strategy compared to the next less costly strategy in intermediate scenario (June 1, 2020 R_e 1.3)



C.
ICER for Symptomatic+asymptomatic-monthly strategy compared to the next less costly strategy in surging scenario (June 1, 2020 R_e 2.0)